Genedrive (LSE:GDR) has appointed Mark Winkler and Mike Fairbourn as independent non-executive directors as the diagnostics company prepares to accelerate the adoption of its pharmacogenetic testing technology in the UK and international markets.
Both appointments will take effect on 1 September 2026 and are intended to add further financial, strategic and healthcare industry expertise to the board as Genedrive moves into its next stage of commercial development.
Winkler brings corporate finance expertise
Mark Winkler is a corporate finance specialist and the founder of Red Earth Advisors. His experience is expected to strengthen Genedrive’s financial oversight and governance as the company pursues its growth strategy.
Following his appointment, Winkler is expected to become chair of both the audit and remuneration committees.
Mike Fairbourn brings more than three decades of commercial and leadership experience across the pharmaceutical and medical technology industries. His career includes senior positions at Becton Dickinson, providing the board with additional expertise in healthcare commercialisation and scaling medical technologies.
Genedrive targets wider clinical adoption
The appointments come as Genedrive focuses on expanding its presence in the UK while developing opportunities for international growth.
Chairman Graham Cole highlighted the importance of strengthening the company’s commercial execution as it seeks to increase adoption of its pharmacogenetic tests and generate sustainable value for shareholders.
The incoming directors have indicated that their priorities will include supporting disciplined expansion, increasing clinical uptake and helping integrate Genedrive’s pharmacogenetic technology more widely into established healthcare pathways.
Long-serving non-executive director Chris Yates has stepped down from the board to pursue other professional commitments.
Financial performance remains a key challenge
Genedrive’s outlook continues to be constrained by its financial position, including substantial ongoing losses, persistent cash consumption and a declining equity base. Relatively low debt provides some balance-sheet support but does not offset the pressures associated with continued negative earnings.
Technical indicators present a somewhat more favourable picture, with the shares trading above major moving averages and momentum measures broadly neutral.
Valuation remains difficult to assess using conventional earnings measures because the company remains loss-making, resulting in a negative price-to-earnings ratio, while there is no dividend yield to provide additional support.
More about Genedrive
Genedrive plc is a UK-based commercial-stage pharmacogenetic diagnostics company developing rapid point-of-care tests designed to help clinicians select safer and more effective drug treatments based on a patient’s genetic profile.
Its portfolio includes the Genedrive CYP2C19 ID Kit, which identifies stroke patients who may be unlikely to respond effectively to standard Clopidogrel treatment, and the Genedrive MT-RNR1 ID Kit, designed to identify newborns at risk of antibiotic-induced hearing loss and support rapid treatment decisions.
Headquartered in Manchester, Genedrive has CE-IVD approved and NICE-recommended technologies deployed within NHS clinical practice. The company is seeking to embed its precision diagnostic tools more widely into routine healthcare pathways while using clinical and real-world evidence to support expansion into international markets.
Leave a Reply